{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-22-000120","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.356962+00:00","generated_at":"2026-06-22T01:18:01.167006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Summit Therapeutics Q3 net loss $21.4M; raised $99.9M net via rights offering","bullets":["Net loss $21.4M for Q3 2022 vs $19.6M prior year; 9-month net loss $59.6M vs $61.5M.","Cash and receivables $138.4M at Sep 30, 2022, up from $89.0M at Dec 31, 2021; cash $122.0M.","Fully subscribed Rights Offering raised $100M gross at $0.97/share, net $99.9M after $0.1M costs.","Proceeds repaid $25M note plus accrued interest to Chairman/CEO Robert Duggan.","Elevated Dr. Mazy Zanganeh to Co-CEO & President; discontinued pediatric ridinilazole trial; seeking partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-22-000120","json":"https://secwatch.observer/filing/0001599298-22-000120.json","markdown":"https://secwatch.observer/filing/0001599298-22-000120.md","text":"https://secwatch.observer/filing/0001599298-22-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000120/0001599298-22-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000120/smmt-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:18:01.167006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0792353e073fefb29cbdef40307babeb40ea0c1b","claim":"Summit Therapeutics Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Summit Therapeutics Inc. (the \"Company\") announced its financial results and operational progress for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000120/0001599298-22-000120-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}